首页> 外文期刊>Oncology letters >Effect of cytokine-induced killer cells on immune function in patients with lung cancer
【24h】

Effect of cytokine-induced killer cells on immune function in patients with lung cancer

机译:细胞因子诱导的杀伤细胞对肺癌患者免疫功能的影响

获取原文
获取原文并翻译 | 示例
           

摘要

Cytokine-induced killer (CIK) cells have been used as adoptive immunotherapy in cancer. The present study evaluated the effect of CIK cells on immune function in patients with lung cancer. Patients were divided into three groups, according to the treatment received prior to CIK cell treatment: CIK group (no prior treatment), Che-Sur group (prior chemotherapy and surgery) and Che-Rad group (prior chemotherapy and radiotherapy). Following treatment, the average percentage of cluster of differentiation (CD)3(+)CD4(+), CD3(+), natural killer (NK) and NKT cells in peripheral blood was significantly higher than that prior to CIK treatment in the Che-Sur and CIK groups, and the levels of interferon- in serum were significantly higher than those prior to CIK treatment in the Che-Sur and CIK groups. On the contrary, the levels of interleukin-10 had decreased in these groups following CIK treatment. Subsequently, patients were divided into three groups according to the percentage of CD3(+)CD56(+) CIK cells that were administered to the patients. The number of NK and NKT cells increased with increasing number of CD3(+)CD56(+) cells. The patients in the CIK and Che-Sur groups were the most benefited ones following CIK treatment, contrarily to those in the Che-Rad group, since the increase in the number of CD3(+)CD56(+) CIK cells in the aforementioned patients enhanced the number of NK cells, which exhibit antitumor activity.
机译:细胞因子诱导的杀伤(CIK)细胞已被用作癌症的过继免疫疗法。本研究评估了CIK细胞对肺癌患者免疫功能的影响。根据在CIK细胞治疗之前接受的治疗,将患者分为三组:CIK组(未进行过预先治疗),Che-Sur组(在化疗和手术之前)和Che-Rad组(在化疗和放疗之前)。治疗后,外周血中分化(CD)3(+)CD4(+),CD3(+),自然杀伤(NK)和NKT细胞簇的平均百分比显着高于车内CIK治疗之前的水平。 -Sur和CIK组以及Che-Sur和CIK组的血清中干扰素水平显着高于CIK治疗之前的水平。相反,CIK治疗后这些组的白细胞介素10水平降低。随后,根据给予患者的CD3(+)CD56(+)CIK细胞的百分比,将患者分为三组。 NK和NKT细胞的数量随CD3(+)CD56(+)细胞数量的增加而增加。 CIK和Che-Sur组的患者是CIK治疗后受益最多的患者,与Che-Rad组的患者相反,因为上述患者CD3(+)CD56(+)CIK细胞的数量增加增强了具有抗肿瘤活性的NK细胞的数量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号